CLINICAL ANATOMY OF THE MIDFACE

Layer 1
The skin varies in thickness, pigmentation, and subcutaneous adherence between different areas of the face. In the buccal and in the parotideomasseteric area, the skin is connected by vascularized septa to the subcutaneous fat layer. In the infraorbital region and medial to the midpupillary line, the skin is thin and in general no subcutaneous fat can be identified there. Inferior to the nasolabial sulcus and medial to labiomental sulcus the skin is firmly attached to the underlying mimetic muscles. This type of strong cutaneous adherence can be also identified between skin and the orbicularis oculi and the orbicularis oris muscle.
Layer 2
The subcutaneous tissue in the midface is strongly vascularized and compartmentalized by fibrous septa. Within these septa, small vessels can (not always) be identified, and these septa have a strong relationship to the underlying mimetic muscles of the face. Being aware of the high variation of the underlying mimetic muscles, it is understandable that the precise boundaries between the subcutaneous fat can vary (Y. Saban, personal communication, 2015) . 1 In Figure 1 , the natural boundaries between the malar fat pad (also called the medial subcutaneous fat pad of the midface 2 ) and the nasolabial subcutaneous fat can be easily identified as the course of the postmortem vascular changes encircle the malar fat pad in this specimen. In Figure 2 , the relevant subcutaneous fat compartments of the midface are depicted for a better understanding. Looking at the lower lid, no subcutaneous fat be found between the palpebral part of the orbicularis oculi muscle and the skin.
Layer 3
The underlying framework of the subcutaneous fat compartments is the SMAS, 3 which can easily be dissected as 1 layer reaching from the neck (=platysma) to the temple (=superficial temporal fascia 4 ) and to the nose (nasal SMAS 5 ). In the periorbital region, the orbicularis oculi muscle can be identified in the same plane (Fig. 3) . Layer 3 has strong connections to layer 5 deep to it. These connections serve as sheltered transit points for nerve branches passing from deep Supplemental digital content is available for this article. Direct URL citations appear in the text; simply type the URL address into any Web browser to access this content. Clickable links to the material are provided in the HTML text of this article on the Journal's website (www. PRSJournal.com). 
Fig. 1.
Cephalus of a fresh-frozen female specimen. The skin of the right side of the face has been removed, and the subcutaneous fat compartments are exposed. The subcutaneous fat is absent over the palpebral part of the orbicularis oculi muscle (*). The tear trough is visible right inferior to the black asterisk. Postmortem vascular changes encircle the malar fat pad and thus delineate the boundaries between the nasolabial and the medial subcutaneous fat compartment (arrows).
Fig. 2.
Cephalus of a fresh-frozen female specimen. The skin of the right side of the face has been removed, and the subcutaneous fat compartments are exposed. The subcutaneous fat compartments of the midface are encircled: 1, nasolabial subcutaneous fat compartment; 2, medial subcutaneous fat compartment; 3, middle subcutaneous fat compartment; 4, lateral subcutaneous fat compartment; *, orbital rim; #, mandibular line.
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is the orbital part of the orbicularis oculi muscle and the SMAS of the midface. The floor is the levator labii superioris alaeque nasi muscle. This compartment is separated from the maxilla by the levator labii superioris alaeque nasi muscle, the structures emerging the infraorbital foramen and in its inferior part by the levator anguli oris muscle and the Ristow's space. 2, 14, 15 Inferior to the medial and lateral part of the DMCF, the buccal space can be identified. The floor of this space is the buccinator muscle, the roof is formed by the mimetic muscles and the SMAS, and the anterior boundary is the modiolus. The superior boundary is the maxillary ligaments, 15 and the inferior boundary is formed of the loose adhesion of the platysma to the mandible. It is of importance to note that this compartment is separated posteriorly from the masticatory space (which includes the buccal fat pad and its buccal extension 16, 17 ) by the facial vein and the masseteric ligaments.
Layer 5
In the lateral part of the midface, layer 5 is formed by the parotideomasseteric fascia. This fascia covers the parotid gland and the parotid duct and includes the buccal branches of the facial nerve. This fascia continues toward the temple over the zygomatic bone and is called there superficial lamina of the deep temporal fascia. Followed anteriorly, this fascia splits up into 2 laminae at the anterior margin of the masseter muscle and forms a "tent-like" space which is attached to the buccinator muscle and closely related to the masseteric ligaments. Inside this space the parotid duct and anterior to it the facial vein can be identified. Superiorly this fascia is attached to the broadly based fibrous attachment of the zygomaticus major muscle. There this delicate arrangement forms an opening through which the facial vein passes deep to the zygomaticus major muscle to run between the lateral and the medial part of the DMCF toward the medial canthus.
Deep to the levator labii superioris muscle, the infraorbital foramen can be found in the midpupillary line. There the infraorbital vessels emerge Fig. 4 . View into the right premasseter compartments of a male fresh-frozen specimen. Dissection is performed in layer 4, that is, between the SMAS (uplifted) and the deep fascia of the face which is here formed by the parotideomasseteric fascia (down). The cross in the left-upper corner of the image shows the orientation. The superior (1), middle (2) , and the inferior (3) premasseter compartments are encircled. Between the inferior and the middle compartment the buccal branch of the facial nerve is marked with an asterisk. The star points to the parotid duct, between the middle and the superior premasseter compartment. Note that both the buccal nerve and the parotid duct pierce the masseteric ligaments at the anterior border of the masseter muscle. The red mark in the image shows the cut edge of the McGregor's patch. The hash mark indicates the zygomaticus major muscle which originates from the zygomatic bone and has in this image been skeletonized for a better visualization. The arrows show the location where the muscle passes through layer 3 to reach the modiolus at the angle of the mouth immediately under the skin (layer 1). PG, parotid gland. the skull in a medial-inferior direction. Inferior to the infraorbital foramen, the bony attachment of the levator anguli oris muscle can be found. These 2 muscles "sandwich" the infraorbital structures.
Infraorbital Hollow
The tear trough area within the infraorbital region can be subdivided in a lateral and a medial part. The boundary between the lateral and the medial part lies 4-6 mm medial to midpupillary line and corresponds to the course of the facial vein. In the lateral part, 7 different layers can be identified: 1, skin; 2, subcutaneous fat layer; 3, orbicularis oculi muscle; 4, sub-orbicularis oculi fat (SOOF); 5, deep fascia (continuation of the superficial lamina of the deep temporal fascia 18 ); 6, preperiosteal (prezygomatic) fat layer; and 7, periosteum. In the medial part (ie, medial to the facial vein), 2 layers can be identified: 1, skin; and 2, orbicularis oculi muscle. The latter is firmly attached to the bone in the medial infraorbital region, and the subdivision into its palpebral and orbital part corresponds to the course of the orbicularis retaining ligament (which is called in this area tear trough ligament and consists of 1 lamina). [19] [20] [21] Laterally the orbicularis retaining ligament consists of 2 laminae and the transition from 2 laminae to 1 single lamina has the aspect of a "Y" as is shown in Figure 6 . The hollow in the medial part of the infraorbital region is formed by the retraction toward the bone of the tear trough ligament of the overlying structures (muscle and skin). The bluish or dark appearance can be partly explained (apart from changes in light shadow or the bulging of nasolabial and medial subcutaneous fat pads) by the thin and thus transparent skin which allows the muscle to shine through. This effect is not unique to the infraorbital hollow but also on the lateral part of nasal wall close to the medial canthus. Another explanation of the bluish appearance might be due to the course of the facial vein in this area.
REGIONAL APPROACHES
Infraorbital Hollows Guy G. Massry, MD; Beverly Hills, Calif. The infraorbital area is a high-risk zone for treatment with hyaluronic acid gel (HAG) fillers as its anatomic construct (little buffer over bone and highly vascular) predisposes to contour irregularities, lumps, bumps, blue discoloration, Plastic and Reconstructive Surgery • November Supplement 2015 hydrophilic reaction, excessive bruising and swelling, and potentially vascular compromise. HAG filling in this area was first reported in 2005. 22 Since then, clinical experience and raw data have demonstrated that product choice and injection technique are critical features of safe and successful infraorbital filling. 23 Although there are many ways to achieve an end, the indiscriminant filling of lines and depressions in the periorbita is a recipe for failure.
The first important criteria for safe and effective infraorbital HAG injection is an awareness that this is a nonforgiving area that is prone to complications even in the hands of the most experience injector. Next, appropriate product selection is essential. Understanding the biochemical composition and flow characteristics of the selected gel (concentration, percent cross-linking, viscosity, G′) will allow correct clinical selection for desired effect and reduce the incidence of the previously listed complications. 23 Finally injection technique, 24, 25 including delivery method (cannula vs needle), and entry point are important. 25 I will briefly outline my injection pearls and product choices which I have found to be consistent, reliable, and generally complication free in this delicate location (see Video, Supplemental Digital Content 3, which demonstrates Dr. Massry's personal technique for using HAG filling for infraorbital hollows, available in the "Related Videos" section of the full-text article on PRSJournal. com or, for Ovid users, at http://links.lww.com/ PRS/B460). HAG fillers are implants (Food and Drug Administration approved for this indication) and should be treated as such. I prepare the skin with a Hibiclens and alcohol wipe prior to injection. 26 I administer regional sensory blocks (infraorbital and zygomaticofacial nerves) for comfort, as this allows definitive freedom and compliance with treatment. A 0.2-mL bolus of 1% plain lidocaine is given to the respective regional nerves. Compression of the injected bolus distributes the fluid as not to mask the local depressions. I prefer a cannula delivery to reduce potential bruising and possibly reduce the incidence of intravascular injection. The entry point is in the upper malar tissue below the orbital rim in line with the central eyelid. This thicker tissue substrate is less prone to bruising than the thinner eyelid skin directly over the infraorbital hollow. 25 This central entry can access the entire lid/cheek transition. A wheel of local anesthetic is given (like a tuberculin skin test) at the injection entry point. A 22-G needle perforates the skin at this location to create an entry port. The gel is administered with a 25-G 1½-inch cannula. A smaller gauge device may eliminate the benefit of a blunt delivery method and is flimsy and less precise. The cannula length allows appropriate treatment of the entire eyelid/cheek interface from this one entry site. The gel can be placed supraperiosteally, below orbicularis, or in very small amounts subcutaneously depending on 
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anatomic deficit and clinical needs. Pulling back on the plunger prior to injection and retrograde injection theoretically reduces the risk of intravascular penetration. Direct massage of gel over bone tends toward more even dispersion of the material (Fig. 7) .
In the infraorbital area, deeper injection of the less distensible (stiffer) and more viscous Restylane product promotes a nice 3-dimensional (3D) tissue expansion (lift and fill), while the less viscous Belotero product allows effacement of more superficial irregularities. I have found these 2 gels to be the most "user friendly" for effacement of lid/cheek interface depressions. In my experience, deep injection of Belotero, while effective, has a shorter clinical duration of effect in terms of lifting and filling than Restylane. Similarly, superficial placement of Restylane tends toward more blue color change and hydrophilic reaction than Belotero. Postinjection, for those patients concerned with swelling, a Medrol dose pack is administered with a broad-spectrum oral antibiotic if not otherwise contraindicated. Patients are asked to say 15 minutes post injection to assure no short-term skin blanching or mottling. As a precautionary measure a hyaluronidase preparation, nitropaste (controversial) and aspirin are on hand for every filler patient.
As a final note, be careful with patient retreatment. Ultrasound studies have shown the persistence of material after clinical effect has resolved. 24 Err on the side of caution in this instance as not to "stack" new on old product, whose combination may predispose to contour changes, edema, and blue color change.
Nose
Steven Liew, MD, FRACS; Sydney, Australia I prefer using hyaluronic acid (HA)-based fillers in the nose due to their established safety, plasticity, durability, and reversibility. I choose HA fillers with characteristics of high gel hardness (G*), cohesivity, and less hydrophilic to provide sustained projection, to reduce risk of spread of product after deposition from the overlying tension of soft tissue, and to minimize swelling from fluid absorption.
My preference is to use a needle to more efficiently place the product in the precise location and anatomical plane especially superficial to caudal septum. (See Video, Supplemental Digital Content 4, which demonstrates Dr. Liew's personal technique for using HA-based fillers in the nose, available in the "Related Videos" section of the fulltext article on PRSJournal.com or, for Ovid users, at http://links.lww.com/PRS/B461.) In addition, widebore cannula and multiple passages of cannula may theoretically create dead space for product spread.
Keep the needle in the midline on the supraperiosteal and supracartilaginous plane and inject Watch for skin blanching and severe localized or distant pain, both during after injection which may suggest vascular compromise.
The optimal position (anterior view, Fig. 8 ) and projection (lateral view, Fig. 9 ) should include a straight dorsum of the nose and with or without a supratip break.
Be cautious of previous rhinoplasty patients. Avoid administering >1 mL in the dorsum in 1 injection session due to risk of product spread from tissue tension.
Prepare to review patient immediately regarding significant postinjection pain, bruising. Rule out ischemia before instructing cold compresses.
Miles Graivier, MD, FACS; Roswell, Ga. Nasal contouring with fillers can be used for cosmetic reasons and structural support of the nose. (See Video, Supplemental Digital Content 5, which demonstrates Dr. Graivier's personal technique for using dermal fillers in the nose, available in the "Related Videos" section of the full-text article on PRSJournal.com or, for Ovid users, at http:// links.lww.com/PRS/B462.) For first-time patients, I recommend using a HAG filler (Restylane, Juvederm, Belotero) because these can be reversed with a hyaluronidase. On the dorsum and sidewalls of the nose, a particulate filler can be used (Radiesse, Bellafill) if previous contouring with an HA was successful and no complications occurred.
Technical pearls and pitfalls:
• Volume varies depending on size of area, number of sites being treated, and if the filler is being used for aesthetic nasal contouring (ie, tip projection and shaping). • In areas of scarring, test with local anesthesia to see if tissue planes dissect without compromise.
Most filler volume ranges from 0.1 to 1.0 mL per injection session. If serial injection planned, patient can return at 4-to 6-week intervals. After full correction achieved, patients return at 3-to 6-month intervals for evaluation and retreatment if necessary.
Vascular compromise can happen with any filler:
• First sign: usually blanching after injection.Recommend: first disperse material with finger massage to displace filler from capillaries. If no resolution after 5-10 minutes, proceed to injection of hyaluronidase, nitro paste, vasodilators, warm compresses, and hyperbaric oxygen therapy.
To be efficacious, the material should fill the defect or smooth the contour in such a way that it generates a natural appearance, with a seamless transition from treated to untreated areas (Fig. 10) . Treat to correction, but stop if blanching or other indication of vascular compromise. Patient can return in 4-6 weeks if more correction necessary.
Soft-tissue fillers should be used with caution in the nose, especially in thin skin and in skin that has been repeatedly traumatized and devascularized, as occurs in patients who have undergone revision rhinoplasty. Use of dermal fillers may also be problematic in areas of the nose where there is dense scarring and adhesions. It should be used with caution in patients with alloplastic material in the nose.
Steve Dayan, MD; Chicago, Ill.
A quick fix for a difficult procedure is an attractive option. And a nonsurgical nasal 
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reshaping procedure with seemingly limited downtime and expense can pose a gravitating mirage for patients. However, filler in the nose carries a risk for disastrous complications. 27 Anatomy, previous surgery, skill, product, and method of delivery all have an impact on the cosmetic outcome and the relative risk for untoward effects. Although there is an indication for filler in the primary nose, it is mostly discouraged in my practice; however, there are situations in which surgery is not an option and filler can be used to create symmetry, a favorable profile and tip projection. Fillers are particularly beneficial for the minor postrhinoplasty dorsal defect in which a small aliquot avoids a revision and provides a lasting solution that immediately meets expectations.
I most often use a 22-G to 27-G cannula entered into the sub-SMAS plane below the major vessels, an important plane for reducing the risk of vascular complication. 28 Aesthetic endpoint is highly variable, dependent on the patient, the situation, and anatomy. Similar to rhinoplasty, it is when patient expectations are met weighed against the risk of further treatment. For cheek reshape, Voluma is the best option due to its lifting capacity to combat sagginess. The versatility to inject it both into subcutaneous and supraperiosteal level, easy-to-mold property, and mainly reversibility are what make this product unique.
The challenge is to deliver appropriate cheek reshape and not simply volumize it or make it fuller. The cheek subunits should be respected as demonstrated below with the "MD Codes." Each cheek subunit is coded as follows: the 5-point cheek reshape-Ck1 (zygomatic arch, V1 for Voluma); Ck2 (zygomatic eminence, V2); Ck3 (anteromedial cheek, V3); Ck4 (parotid area); and Ck5 (submalar area) (Fig. 11) . The latter are represented as V4 also for Voluma (Fig. 12) . It is important to fight gravity first by creating structural support (Ck1 and Ck2) and then correct volume loss (Ck3, Ck4, and Ck5). 29 As a result, appropriate cheek architecture is obtained. Anchoring the cheek with a single big bolus or injecting at random will not provide optimal contour and may lead to unnatural results especially on animation.
The aesthetic endpoint should be assessed with the patient on animation (full smile), as well as in different positions such as oblique, profile, and tilting down. Excessive cheek lifting on animation or "sausage-like fold" on the cheek should be avoided.
I use preferably needles (27 G) when deep injections onto the bone are required. Proper aspiration is mandatory. (See Video, Supplemental 
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Digital Content 7, which demonstrates Dr. de Maio's personal technique for cheek reshaping using Voluma, available in the "Related Videos" section of the full-text article on PRSJournal.com or, for Ovid users, at http://links.lww.com/PRS/ B464.) Cannulas (25 G) are advisable into the midcheek (close to infraorbital foramen) and parotid areas if comprehensive work is needed.
Rebecca Fitzgerald, MD; Los Angeles, Calif. Fear of unnatural appearing results is a common concern voiced by patients new to injectable treatments. In fact, natural-looking results are desirable to both the patients and the physicians treating them. Newer understanding of the compartmentalization of facial fat both superficial and deep to the facial muscles may be helpful in achieving this goal. Here, I am using 1 mL of Voluma (Allergan, Irvine, Calif.), which has been diluted with 0.5-mL normal saline, and I am injecting with a 26-G needle. This was done to make it easier for me to reflux with one hand prior to injection as well as to enable use of the product in the SOOF (undiluted product may clump in this area). Although I routinely use cannulas, both a needle and a cannula were used here to demonstrate both. A total of 3 mL of Voluma was used in this treatment session.
The purpose of this video is to demonstrate placement of a filler into the deep fat compartments of the mid face-specifically the SOOF and the DMCF. (See Video, Supplemental Digital Content 8, which demonstrates Dr. Fitzgerald's personal technique for placing filler into the deep fat compartments of the mid face-specifically the SOOF, available in the "Related Videos" section of the full-text article on PRSJournal.com or, for Ovid users, at http://links.lww.com/PRS/B465.) Both of these deep midfacial compartments exist in discrete medial and lateral compartments and are colored green in Figure 13 .
2 Ristow's space, a potential space which exists between the periosteum of the maxilla and the DMCF, is also pictured. These deep compartments give anterior projection to the midface and provide us with a "site-specific target," which yields predictable, consistent, and natural-looking results in the midface. The variable depth of a nasolabial fold or tear trough is likely related to the presence or absence of this deep fat which can be appreciated by the computer tomographic image of a cadaver after injection of radio-opaque dye into the medial aspect of the DMCF compartment (Fig. 14) . 30 Filling the DMCF prior to the SOOF may decrease the amount of filler needed in the higher compartments. Filler in the area of Ristow's space then lifts this overlying tissue without distorting the natural topography. As we are all now aware, too much filler, especially when placed too high, in the medial aspect of the cheek or tear trough can give an abnormal appearing convexity in the infraorbital area as well as an abnormally prominent medial cheek on animation.
In general, a nice result can be obtained with a conservative amount of product in most patients. Be aware that very empty faces (from age, disease, or endurance exercise) may require a lot of product to fill-this can then be discussed with the patient prior to treatment. Additionally, in patients with advanced elastosis of their outer skin envelope it may be difficult to appreciate the fill without a great deal of product.
The endpoint is too fill to the point that lifts the overlying tissue and softens the shadowing in the midface. The degree of improvement possible or even desired by the patient is variable according to age, degree of volume loss, and integrity of the outer skin envelope.
Safety here primarily concerns the avoidance of inadvertent intravascular injection. Many named vessels including the zygomaticofacial, infraorbital, and angular artery run through the midface. All of the usual precautions should be taken, that is, slow, low-pressure injections with small amounts of product through a constantly moving needle, to keep the reaction as localized as possible in the event it does occur. 31 I routinely dilute HA and use this with 26-G needles to reflux prior to every injection (although it should be noted that there are no data yet available on the efficacy or reliability of this maneuver). I also use cannulas routinely around the eye as this helps locate the position of the orbital retaining ligament when injecting in this area to avoid inadvertent postseptal injections. In my hands, cannulas have also greatly decreased the amount of bruising associated with these injections.
Finally, antiseptic technique is important when injecting long-lasting fillers through the skin. I use 2% chlorhexidine with sterile water (not tap water) followed by 70% alcohol. Imagine 3D radial expansion of zygomatic bone and superolateral portion of maxilla. Need not involve complete expansion but may be preferentially superior portion, inferior portion, lateral portion, etc. as needed to create appropriate midface convexity.
Simultaneous treatment of other facial areas with immediate (nondelayed) volumizers (HA, calcium hydroxylapatite, etc.) can be performed but should involve pretreatment patient education regarding anticipated facial appearance during the 3 months following the initial treatment. That is, treatment will yield a desirable 3D contour at the time of treatment. However, 1 week later, the midface will temporarily devolumize and then slowly improve over the following 12 weeks. Two additional treatments typically will be scheduled at 4 and 10 weeks after initial treatment date.
All patients encouraged to take posttreatment vitamin C and zinc (100% recommended daily allowance) supplements for 3 months.
The aesthetic endpoint is not necessarily visualized at treatment time. Rather, endpoint is "sufficient" product to assure maximum stimulation. For typical female face, this ranges from 2.0 to 3.0 mL in supraperiosteum and 1.5 to 3.0 mL in subdermis; assumption: 9 mL reconstitution of product (7 mL, Bacteriostatic Water, 2 mL, 1% lidocaine with epinephrine 1:100,000).
Safety considerations: Subdermal application should remain uniform in depth to maximize uniformity of response. Supraperiosteal injection should involve aspiration prior to injection with each depot injection to rule out intra-arterial placement of needle tip. If we look with "new eyes" at our aesthetic patients faces clinically and in our detailed study of their photographs, we discover that youthful faces have light and shadows all in just the right places.
Facial shadows are not simply dark areas that border the light. These shadows are as important as the light in giving life to the face. It is the facial shadows that shape the light and focus our attention to the light. For example, talented makeup artists understand that you cannot have shadows without light and you cannot have facial highlights without shadows. Photography experts have taught us that photography is the language of light and shadows and in fact photography literally means-writing with light.
You must have light to see, but even with light it does not mean you will have "vision." In aesthetics, to see clearly do not just look at the facial highlights but also focus on the shadows. Understanding and paying keen attention to facial shadows are often very enlightening, as the less obvious is often hiding in plain sight.
The use of an aesthetic blueprint for treating the cheek and other key facial areas creates better balance between light and shadows. I use the aid of Golden Mean Calipers in designing the blueprint for this math-art project. The youthful cheek "form shadow" should be left untreated as this helps re-create the cheek highlights we associate with a healthy youthful natural-looking face.
We teach our aesthetic patients that getting older is not optional but looking older is. Restoration and facial maintenance is a choice, but doing nothing is also a choice. Some of my patients say "I just want grow old gracefully". What this means is you grow older and look it. Maturing gracefully means you make a choice to look age appropriate and with careful maintenance you will start having increasing comments from those that have chosen to do nothing-these comments are usually "you always just look the same."
It is a bit of a paradox that we, as aesthetic practitioners, can create and maintain a youthful appearance for our patients through facial maintenance with HA fillers and neuromodulators. With the right blueprint, this is a very clever sleight of hand in facial aesthetics. Looking great is the best thing you can wear. 
